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Abstract
Introduction: HJURP (Holliday Junction Recognition Protein) is a newly discovered gene reported to function at
centromeres and to interact with CENPA. However its role in tumor development remains largely unknown. The
goal of this study was to investigate the clinical significance of HJURP in breast cancer and its correlation with
radiotherapeutic outcome.
Methods: We measured HJURP expression level in human breast cancer cell lines and primary breast cancers by
Western blot and/or by Affymetrix Microarray; and determined its associations with clinical variables using standard
statistical methods. Validation was performed with the use of published microarray data. We assessed cell growth
and apoptosis of breast cancer cells after radiation using high-content image analysis.
Results: HJURP was expressed at higher level in breast cancer than in normal breast tissue. HJURP mRNA levels
were significantly associated with estrogen receptor (ER), progesterone receptor (PR), Scarff-Bloom-Richardson (SBR)
grade, age and Ki67 proliferation indices, but not with pathologic stage, ERBB2, tumor size, or lymph node status.
Higher HJURP mRNA levels significantly decreased disease-free and overall survival. HJURP mRNA levels predicted
the prognosis better than Ki67 proliferation indices. In a multivariate Cox proportional-hazard regression, including
clinical variables as covariates, HJURP mRNA levels remained an independent prognostic factor for disease-free and
overall survival. In addition HJURP mRNA levels were an independent prognostic factor over molecular subtypes
(normal like, luminal, Erbb2 and basal). Poor clinical outcomes among patients with high HJURP expression were
validated in five additional breast cancer cohorts. Furthermore, the patients with high HJURP levels were much
more sensitive to radiotherapy. In vitro studies in breast cancer cell lines showed that cells with high HJURP levels
were more sensitive to radiation treatment and had a higher rate of apoptosis than those with low levels. Knock
down of HJURP in human breast cancer cells using shRNA reduced the sensitivity to radiation treatment. HJURP
mRNA levels were significantly correlated with CENPA mRNA levels.
Conclusions: HJURP mRNA level is a prognostic factor for disease-free and overall survival in patients with breast
cancer and is a predictive biomarker for sensitivity to radiotherapy.
Introduction
The centromere has long been recognized as a locus
important for proper cell division and accurate parti-
tioning of chromosomes into daughter cells [1-3]. Cen-
tromeres are the chromatin regions associated with
kinetochores, which are massive multi-protein
complexes that mediate chromosome segregation and
the mitotic checkpoint [4]. There is mounting evidence
that kinetochores become functionally unstable during
oncogenesis resulting in segregation defects, chromo-
some instability, and cancer development [4-6].
Holliday Junction Recognition Protein (HJURP, also
known as hFLEG1), which is a newly discovered gene,
was reported to be overexpressed in lung cancer cells
through genome-wide expression profile analysis [7]. By
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quantitative RT-PCR, Valente et al found that the
HJURP expression levels significantly differ between
glioblastoma resection tumor and non-neoplastic white
matter [8]. Additionally it was observed that the expres-
sion level of HJURP in glioblastoma was changed
about nine fold compared to typically benign pilocytic
astrocytomas by microarray profile analysis [9]. It has
also been reported that HJURP is involved in DNA dou-
ble-strand break repair pathway through interaction
with MSH5 and NBS1 [7]. Recently two groups have
shown that HJURP functions at the level of the centro-
mere, and is required for centromere protein A
(CENPA) centromeric localization, for loading of new
CENPA nucleosomes, and for accurate chromosomal
segregation [10-12]. A majority of cancer cells tend to
gain and lose chromosomes at each mitotic division and
are found to be aneuploid and chromosomally instable.
Thus these findings support the hypothesis that altera-
tions in HJURP might play an important role in cancer
development. We investigated whether altered expres-
sion levels of HJURP are associated with adverse clinical
outcomes using cohorts of patients with breast cancer.
Materials and methods
Cell lines and cell lysates
The names of cell lines used in our investigations are
listed in Table 1. The derivation, sources, and mainte-
nance of most of the breast cancer cell lines used in this
study have been reported previously [13] or were pro-
vided in Table 2. These cell lines have been previously
analyzed for genomic aberrations by comparative geno-
mic hybridization (CGH) and for gene-expression pro-
files using Affymetrix microarrays (Santa Clara, CA,
USA) [13]. The information on growth conditions of
additional cell lines was listed in Table 2. Cells at 50%
to 75% confluence were washed in ice-cold phosphate
buffered saline (PBS). Then cells were extracted with a
lysis buffer (containing 50 mM HEPES (pH 7.5), 150
mM NaCl, 25 mM b-glycerophosphate, 25 mM NaF,
5 mM EGTA, 1 mM EDTA, 15 mM pyrophosphate,
2 mM sodium orthovanadate, 10 mM sodium molyb-
date, 1% Nonidet-P40, 10 mg/ml leupeptin, 10 mg/ml
aprotinin, and 1 mM PMSF). Cell lysates were then clar-
ified by centrifugation and frozen at -80°C. Protein con-
centrations were determined using the Bio-Rad BCA
protein assay kit (Cat# 23227, Pierce Biotechnology,
Rockford, IL, USA).
Western blot
For Western blots, 10 μg of protein extracts per lane were
electrophoresed with denaturing sodium doedecyl sulfate
(SDS)-polyacrylamide gels (4% to 12%), transferred to
PVDF membranes (Millipore, Temecula, CA, USA), and
incubated with HJURP antibody 1:500 (Rabbit,
HPA008436, Sigma-Aldrich, St. Louis, MO, USA) and
actin (goat, sc-1616, Santa Cruz Biotechnology, Santa
Cruz, CA, USA) diluted with blocking buffer (927-40000,
LI-COR Biosciences, Lincoln, NE, USA) The membranes
were washed four times with TBST and treated with
1:10,000 dilution of Alex Fluor 680 donkey anti-rabbit
(A10043, Invitrogen, Carlsbad, CA, USA) and IRDye
800CW conjugated donkey anti-goat (611-731-127, Rock-
land, Gilbertsville, PA, USA) to detect HJURP and actin
respectively. The signals were detected by infrared imaging
(LI-COR Biosciences, Lincoln, NE, USA). Images were
recorded as TIFF files for quantification.
Protein quantification
Protein levels were measured by quantifying infrared ima-
ging recorded from labeled antibodies using Scion Image
[14]. For each protein, the blots were made for 7 sets of 11
cell lines, each set including the same pair (SKBR3 and
MCF12A) to permit intensity normalization across sets. A
basic multiplicative normalization was carried out by
Table 1 The list of breast cancer cell lines and immortalized non-malignant mammary epithelial cells used in these
investigations.
Set 1 Set 2 Set 3 Set 4 Set 5 Set 6 Set 7
Lane Name Lane Name Lane Name Lane Name Lane Name Lane Name Lane Name
1 SKBR3 1 SKBR3 1 SKBR3 1 SKBR3 1 SKBR3 1 SKBR3 1 SKBR3
2 MCF12A 2 MCF12A 2 MCF12A 2 MCF12A 2 MCF12A 2 MCF12A 2 MCF12A
3 600MPE 12 MDAMB134 21 BT483 30 184A1N4 39 DU4475 48 HCC1395 57 MX-1
4 AU565 13 MDAMB157 22 HCC70 31 184B5 40 SUM1315M02 49 HCC1428 58 SUM102
5 BT20 14 MDAMB175 23 HCC1187 32 HCC38 41 HCC1954 50 HCC1806 59 SUM190
6 BT474 15 MDAMB231 24 HCC1500 33 HCC202 42 SUM44PE 51 HCC1937 60 HCC1419
7 BT549 16 MDAMB361 25 MCF10A 34 HCC1143 43 SUM52PE 52 HCC2185 61 HCC3153
8 CAMA1 17 MDAMB415 26 MDAMB453 35 HCC1569 44 SUM149PT 53 HCC2218 62 S1
9 HBL100 18 MDAMB435 27 ZR751 36 HCC1599 45 SUM159PT 54 HCC1599 63 T4
10 Hs578T 19 T47D 28 ZR7530 37 LY2 46 SUM185PE 55 UACC893 64 MDAMB231-Gray
11 MCF7 20 UACC812 29 ZR75B 38 SUM225 47 SUM225CWN 56 SUM229 65 MDAMB231-ATCC
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fitting a linear mixed effects model to log intensity values,
and adjusting within each set to equalize the log intensities
of the pair of reference cell lines across the sets.
Tumor samples
Detailed patient information has been described in our
previous studies [15]. This analysis is based on pre-
viously reported comparative genomic hybridization
(CGH) and a gene expression profile of 130 tumors
from UC San Francisco and the California Pacific Medi-
cal Center collected between 1989 and 1997.
Validation
The association of HJURP expression levels and survival
among patients with breast tumors was examined in exist-
ing microarray data sets of primary tumor samples that
had been profiled with an Affymetrix microarray assay
(either HG-U133A or HG U133 Plus 2.0) ((GEO:
GSE1456), (GEO:GSE7390), (GEO:GSE2034), (GEO:
GSE4922)) or Agilent oligo microarray (Santa Clara, CA,
USA)(Table 3). Probe 218726_at and 20366 (GenBank:
NM_018410) were used to measure HJURP expression in
Affymetrix and Agilent GeneChip, respectively. The pro-
cess data from GEO website were downloaded for analysis.
HJURP shRNA construct
The shRNA sequences were (forward) 5'-GATCCCC
GAGCGATTCATCTTCATCA TTCAAGAGA TGAT-
GAAGATGAATCGCTC TTTTTGGAAA-3' and (reverse)
5'-AGCT TTTCCAAAAA GAGCGATTCATCTTCATCA
TCTCTTGAA TGATGAAGATGAATCGCTC GGG-3'
synthesized from IDT (Integrated DNA Technologies, Inc.,
San Diego, CA, USA). HJURP shRNA was cloned into BglII
and HindIII cleavage sites of pSUPER.retro.puro vector
based on manufactory’s instruction (OligoEngine, Seattle,
WA, USA). HJURP shRNA expression vector were con-
firmed by direct DNA sequencing.
Retroviral packaging and infection
HJURP shRNA (or empty) retroviral vectors along with
packaging system pHit60 and pVSVG vectors were then
co-transfected into the HEK 293 Phoenix ampho packa-
ging cells (ATCC, Manassas, VA, USA) by using
FuGENE6 transfection reagent (Roche, Lewes, UK)
according to the instruction to produce retroviral super-
natants. Forty-eight hours after transfection, the virus-
containing supernatant was filtered through a 0.45 μm
Table 2 Additional cell line growth conditions and subtypes
Lane Name Subtype* Medium Culture condition
30 184A1N4 N MEGMa 37°C, 5% CO2
31 184B5 N MEGMa 37°C, 5% CO2
36 HCC1599 Basal A RPMI1640+10%FBSb 37°C, 5% CO2
48 HCC1395 Basal B RPMI1640+10%FBS 37°C, 5% CO2
50 HCC1806 Basal A RPMI1640+10%FBS 37°C, 5% CO2
53 HCC2218 Luminal RPMI1640+10%FBS 37°C, 5% CO2
54 HCC1599 Basal A RPMI1640+10%FBS 37°C, 5% CO2
55 UACC893 Luminal DMEM+10% FBS 37°C, 5% CO2
56 SUM229PE N/A Ham’s F12+5% FBS+IHc 37°C, 5% CO2
57 MX-1 N/A RPMI1640+10%FBS 37°C, 5% CO2
58 SUM102PT Basal A Ham’s F12+IHEd 37°C, 5% CO2
60 HCC1419 Luminal RPMI1640+10%FBS 37°C, 5% CO2
62 S1 N H14 medium +10 ng/ml EGF 37°C, 5% CO2
63 T4 Basal B H14 mediume 37°C, 5% CO2
64 MDAMB231-Gray Basal B DMEM+10% FBS 37°C, 5% CO2
65 MDAMB231-ATCC Basal B DMEM+10% FBS 37°C, 5% CO2
a: Clonetics MEBM (no Bi Carbonate)+Insulin(5 ug/ml)+Transferrin(5 ug/ml)+Hydrocortisone(0.5 ug/ml) +EGF(5 ng/ml) +Isoprorternol
b: Fetal bovine serum (FBS)
c: Ham’s F12 + 5% FBS + IH {insulin (5 ug/ml) + Hydrocortisone (1 ug/ml) + HEPES (10 mM)}
d: Ham’s F12 + IHE {insulin (5 ug/ml) + HEPES (10 mM) + EGF (10 ng/ml)}
e: H14 medium: DMEM/F12 (GIBCO/BRL) with 250 ng/ml insulin, 10 μg/ml transferrin, 2.6 ng/ml sodium selenite, 10-10 M estradiol, 1.4 × 10-6 M
*: N: non-malignant(immortalized), N/A: no data
Table 3 Information of gene expression datasets used in
this study
Dataset GEO access number
or web location
Radiotherapy Reference
1 GSE1456 Not available [21]
2 GSE7390 Not available [22]
3 NKI [26] 82.4% patients [23]
4 GSE2034 86.7% patients [24]
5 GSE4922 Not available [25]
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syringe filter. Retroviral infection was performed by add-
ing filtered supernatant to a MDAMB231 cell line cul-
tured on 10 cm dishes with 50% confluent in the
presence 4 ug/ml of polybrene (Sigma, St. Louis, MO,
USA). Six hours after infection, the medium was chan-
ged with fresh medium. After 48 hours, infected cells
were selected by adding 5 μg/ml puromycin (Sigma) to
the culture medium for 72 hours and then
maintained in complete medium with 2 μg/ml puromy-
cin. Down-regulation of HJURP expression was con-
firmed by Western blot analysis.
High content imaging to assess cell number and
apoptotic cells
The effects on cell growth and apoptosis were assessed
by a Cellomics high-content image screening system
(Cellomics, Thermo Fisher Scientfic Inc., Pittsburgh, PA,
USA) after breast cancer cells exposed to a single dose
of 0 (sham), 1, 2, 4, 6, 8 or 10 Gy X-ray radiation
emitted from an irradiator (model 43855F, Faxitron X-
ray Corporation, Lincolnshire, IL, USA). Live cells in 96
well plates with six replicates from each treatment were
stained with 1 μmol/L YO-PRO-1 positive cells.
Statistical analysis
Spearman’s correlation coefficient and test were used to
examine the relationship between HJURP mRNA level
and its protein level in the cell line studies, and the rela-
tionship with age, tumor size in the tumor studies, and
CENPA mRNA level. The association between HJURP
mRNA level and clinical factors, such as estrogen recep-
tor (ER), progesterone receptor (PR), ERBB2 and lymph
node status, pathological stage, Scarff-Bloom-Richardson
(SBR) grade, was analyzed by Mann-Whitney U (for two
groups) or Kruskal-Wallis H (for more than two groups)
test. Kaplan-Meier plots were constructed and a long-
rank test was used to determine differences among dis-
ease free and overall survival curves according to HJURP
expression level or radiotherapy. Multivariate analyses
were carried out to examine whether HJURP expression
is an independent prognostic factor for survival when
adjusting for other covariates (age, ER, PR, lymph node,
pathologic stage, SBR grade, tumor size) or the molecu-
lar subtypes (normal like, luminal, Erbb2 and Basal)
using Cox proportional-hazard regression. In addition,
the relation between HJURP expression and survival was
explored in microarray data sets by dividing the cases
from each cohort into a group with high (top one-
third), moderate (middle one-third), and low (bottom
one-third) level of expression. All analyses were
performed by SPSS 11.5.0 for Windows. A two-tailed
P-value of less than 0.05 was considered to indicate
statistical significance.
Results
HJURP is overexpressed in breast cancer
We examined the protein levels of HJURP in a large
panel of human breast cancer cell lines and immorta-
lized non-malignant mammary epithelial cells, which
have been analyzed for genomic aberrations by com-
parative genomic hybridization (CGH) and for gene-
expression profiles using Affymetrix microarrays [13].
Although we found few genetic alterations in the
HJURP locus by inspection of these CGH microarray
data, the protein levels of HJURP were elevated in about
50% of these breast cancer cell lines when compared to
immortalized but non-malignant mammary epithelial
cells 184A1N4, 184B5, and S1 (Figure 1a, b). In order to
determine whether mRNA expression reflected protein
levels, we quantified and normalized HJURP protein
expression in each cell line and demonstrated a signifi-
cant correlation between mRNA expression and protein
levels (the Affymetrix probe for HJURP is 218726_at:
Spearman’s correlation coefficient R = 0.55, P < 0.001;
Figure 1c). Next we examined whether HJURP protein
level is associated with cell proliferation. In order to do
so, we measured the doubling time for each cell line
and found that the doubling time of cell lines was nega-
tively correlated with HJURP protein levels (Spearman’s
correlation coefficient R = -0.395, P = 0.005; Figure 1d).
Furthermore, HJURP mRNA levels in invasive ductal
carcinomas (IDC) were statistically significantly higher
than its levels in the normal breast ducts (P < 0.0001)
(Figure 1e) [16].
HJURP mRNA level is an independent prognostic
biomarker for poor clinical outcome
We assessed the association between HJURP mRNA
levels and clinical factors and outcomes using a
cohort of breast cancer patients in our previous stu-
dies [15]. HJURP expression level is measured as log2
(probe intensities) by Affymetrix microarray. In uni-
variate analysis, HJURP mRNA levels were not asso-
ciated with pathological stage, tumor size, ERBB2
positive, or lymph node positive status (Figure 2a, b,
c, d). However, high HJURP mRNA levels were sig-
nificantly associated with estrogen-receptor negative
(ER-) (P < 0.0001), progesterone-receptor negative
(PR-) P < 0.0001), advanced SBR grade (P < 0.0001),
young age (P < 0.001) and Ki67 proliferation indices
(P < 0.001) (Figure 2e, f, g, h, i). When we divided
HJURP expression levels into three groups (low =
bottom third, moderate = middle third, and high =
top third), patients whose tumor with high HJURP
expression levels had significantly shorter disease
free survival (P = 0.0009) and overall survival (P =
0.0017) period using a Kaplan-Meier log rank
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Figure 1 HJURP is overexpressed in human breast cancer cell lines and primary breast tumors. (a) Protein levels of HJURP (Holliday
junction recognition protein) in a large panel of human breast cancer cell lines and immortalized non-malignant mammary epithelial cells were
assessed by Western blotting. Samples 30, 31 and 62 are immortalized non-malignant mammary epithelial cells 184A1N4, 184B5 and S1
respectively. (b) Normalized quantification of HJURP protein levels in the cell lines using Scion Image software are shown. The arrows indicate
the immortalized non-malignant mammary epithelial cells 184A1N4, 184B5, and S1 respectively. The line shows M+1.95*SE where M is mean of
184A1N4, 184B5 and S1 protein levels and SE is standard error of 184A1N4, 184B5 and S1 protein levels. Protein level above this line was
defined as overexpression. About 50% breast cancer cell lines have overexpression of HJURP. (c) Figure 1c shows the correlation between mRNA
and protein levels of HJURP in human breast cancer cell lines. HJURP expression is measured as log2 (probe intensities) by Affymetrix microarray.
The detail for protein quantification refers to Materials and Methods. R was Spearman’s rho correlation coefficient. The two-tailed P -value was
obtained from Spearman correlation test. (d) The HJURP protein level has a negative and significant correlation with the doubling times of cell
lines. (e) HJURP mRNA expression level is significantly evaluated in invasive ductal carcinomas (IDC) in comparison to normal breast ducts. HJURP
mRNA expression is assessed by Affymetrix microarray. HJURP expression is measured as log2 (probe intensities). The microarray data were found
in Gene Expression Omnibus (GEO) database GEO accession numbers [GEO:GSE10780] [16].
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analysis (Figure 3a). Interestingly, although HJURP
expression significantly correlated with Ki67 prolif-
eration indices, Ki67 proliferation indices are not sig-
nificantly associated with both disease-free and
overall survival (Figure 3b).
In multivariate analyses (including age, pathological
stage, SBR grade, ER status, PR status, lymph node sta-
tus, tumor size, HJURP mRNA levels), lymph node
positive and high pathological stage were associated
with poor disease free survival, whereas lymph node
positive, big tumor size, and age were associated with
poor overall survival (Table 4). HJURP expression level
is an indicator of a poor prognosis for disease-free survi-
val (hazard ratio, 2.05; 95% CI, 1.18 to 3.58; P = 0.011),
and for overall survival (hazard ratio, 1.83; 95% CI, 1.11
to 3.01; P = 0.018) (Table 4).
Figure 2 Association of HJURP mRNA levels with clinic and pathological factors in patients with breast cancer. There was no significant
association between HJUPR mRNA levels and (a) ERBB2 (erythroblastic leukemia viral oncogene homolog 2) status, or (b) lymph node status, or
(c) pathological stage or (d) tumor size. There were significant higher mRNA levels of HJURP in (e) estrogen receptor (ER) negative patients, (f)
progesterone receptor (PR) negative patients; higher mRNA levels of HJURP were significantly associated with (g) high SBR grade, (h) younger
age, and (i) Ki67 proliferation indices. HJURP expression is measured as log2 (probe intensities) by Affymetrix microarray. The two-tailed P-values
were obtained by Mann-Whitney U test for ERBB2, lymph node, ER and PR status, Kruskal-Wallis H test for pathological stage and SBR grade, and
Spearman correlation for size, age, and Ki67 proliferation indices.
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Figure 3 The impact of HJURP expression and Ki67 proliferation indices on the disease-free and overall survival. Figure 3 shows Kaplan-
Meier survival curves for breast cancer patients according to tumor expression of HJURP. The patients from each cohort were divided into a
group with high (top one-third), moderate (middle one-third) and low (bottom one-third) level of HJURP expression. HJURP expression is
measured log2 (probe intensities) as in the microarray. The same criteria were used for Ki67 proliferation indices. HJURP mRNA expression was a
significant prognostic factor for disease-free and overall survival, whereas Ki67 proliferation indices were not significantly associated with
prognosis. (a) Kaplan-Meier survival curves for disease-free and overall survival are presented, while (b) shows the Kaplan-Meier survival curves
for disease-free and overall survival based on Ki67 proliferation indices. The P-values shown were obtained from a long-rank test.
Table 4 Results of multivariate analysis of independent prognostic factors in patients with breast cancer using Cox
regression
Disease-Free survival Overall survival
Factor Hazard ratio (95% CI) P value Hazard ratio (95% CI) P value
HJURP expression+ 2.05 (1.18 to 3.58) 0.011 1.83 (1.11 to 3.01) 0.018
Lymph node (positive) 3.76 (1.16 to 12.25) 0.028 2.72 (1.08 to 6.88) 0.035
High Stage 2.23 (1.08 to 4.59) 0.030 1.85 (0.94 to 3.63) 0.075
Tumor size 1.32 (0.97 to 1.79) 0.079 1.34 (1.02 to 1.77) 0.038
Age (year) 1.01 (0.99 to 1.05) 0.33 1.03 (1.004 to 1.053) 0.022
High SBR Grade 0.76 (0.33 to 1.75) 0.52 1.00 (0.50 to 2.00) 0.99
ER (positive) 0.63 (0.21 to 1.94) 0.42 0.86 (0.33 to 2.25) 0.75
PR (positive) 0.90 (0.33 to 2.50) 0.84 0.95 (0.40 to 2.26) 0.91
+ HJURP expression is measured as log2 (probe intensities) by Affymetrix microarray
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To validate our findings, we used several independent
breast cancer cohorts with previously reported
microarray data deposited in the Gene Expression
Omnibus (GEO) database [17], to compare mRNA level
of HJURP in tumor tissue with patient survival (Table
3). In agreement with our initial findings, decreased dis-
ease-free and overall survival rate was associated with
high mRNA level of HJURP in all of the datasets (Fig-
ures 4 and 5).
Finally, we investigated whether HJURP mRNA levels
were an independent prognostic factor over molecular
subtypes (normal like, luminal, Erbb2 and basal) using
Cox regression. In order to do so, three data sets (refer-
ence 14, Dataset 1 and 3), in which the information of
the molecular subtypes was available, were combined
because there were few patients in each subtype using
each data set. As showed in Table 5, both HJURP
mRNA levels and molecular subtypes were indepen-
dently significantly associated with survival.
HJURP mRNA level predicts the sensitivity to radiation
treatment in breast cancer patients and cell lines
It has been reported that HJURP is involved in the DNA
repair pathway, thus next we investigated whether the
HJURP mRNA level is a predictive marker for radiother-
apy in our cohort of breast cancer patients. As shown in
Figure 6a, the radiotherapy significantly increased dis-
ease-free survival of patients within the high HJURP
mRNA level group (P = 0.022) whereas radiotherapy
did not within the low HJURP mRNA level group. The
data showed a trend toward increased overall survival
within the high and moderate HJURP mRNA level
group (Figure 6b).
In order to confirm the relationship between HJURP
mRNA levels and radiation sensitivity, we selected two
cell lines, one had high levels of HJURP (MDAMB231),
the other had a low level of HJURP (T47D), and treated
them with different doses of x-ray irradiation. Seventy-
two hours after radiation, we measured cell growth and
apoptosis using high-content image analysis. Our data
showed that the response to radiation in breast cancer
cell line MDAMB231 (IC50 = 3.5 Gy) was more sensi-
tive than T47D (IC50 = 8.6 Gy) (Figure 7a). Consistent
with radiation sensitivity, MDAMB231 cells had ahigher
rate of apoptosis than T47D cells (Figure 7b). Similar
results were found in additional cell lines BT20 with
high levels of HJURP and MCF10A with low levels of
HJURP (Figure 7c, d). Finally we designed small interfer-
ing RNA (shRNA) against HJURP and generated stable
transfectants in a human breast cancer cell line
(MDAMB231). The shRNA down-regulated HJURP pro-
tein levels by 75%, as assessed by Western blotting
assays (Figure 7e). Knockdown of the HJURP gene
reduced the sensitivity to radiation (Figure 7f).
Co-overexpression of HJURP and CENPA in breast cancer
Recently it has been shown that HJURP interacts with
CENPA for localization to centromeres and for accurate
chromosome segregation. Thus we examined the expres-
sion pattern between HJURP and CENPA at the mRNA
level. Surprisingly, HJURP levels were significantly and
positively correlated with CENPA levels in human breast
cancer cell lines (Figure 8a) and primary breast tumors
(Figure 8b). Such highly significant correlation was con-
firmed in four independent cohorts with breast tumors
(Figure 8c, d, e, f).
Discussion
The current study is the first to report that HJURP is
overexpressed in breast cancer cell lines and primary
human breast cancer compared to non-malignant
human mammary epithelial cells and normal breast tis-
sues. High HJURP mRNA expression is significantly
associated with both shorter disease-free and overall
survival which were validated in five independent clini-
cal datasets for breast cancer. Furthermore, HJURP is a
predictive marker for sensitivity of radiotherapy, indicat-
ing levels of HJURP mRNA and protein in breast cancer
patients are clinically relevant.
Although we found HJURP mRNA levels were not
associated with ERBB2 status, the mRNA levels of
HJURP was still found significantly higher in triple-nega-
tive (ER negative, PR negative, ERBB2/HER2/neu not
overexpressed) breast cancer, possibly due to the fact
that a higher HJURP mRNA level is significantly asso-
ciated with ER or PR negative status. Triple negative
breast cancer has distinct clinical and pathological fea-
tures, and also has relatively poor prognosis and aggres-
sive behavior [18-20], consistent with our finding that
high HJURP expression is associated with a bad prog-
nosis. Furthermore, our studies showed that the prog-
nostic effect of HJURP mRNA level on survival is
independent of the clinical factors, such as age, lymph
node, pathological stage, SBR grade, ER, PR, tumor size,
and the molecular subtypes. In addition, we found there
is a significant correlation between HJURP expression
and Ki67 proliferation indices; however, HJURP expres-
sion is a better biomarker than Ki67 proliferation
indices for the predication of prognosis.
It is very interesting to find that the HJURP mRNA
level is a predictive marker for radiotherapy sensitivity.
Our results showed that patients with low mRNA levels
of HJURP already had a good prognosis and could not
get further benefit from radiotherapy, suggesting these
patients may not necessarily benefit from receiving
radiotherapy. However, patients with high HJURP
mRNA levels could increase their survival with radio-
therapy, but they still had a worse prognosis than those
with low levels as found in Dataset 3 (Figure 4c) and
Hu et al. Breast Cancer Research 2010, 12:R18
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Figure 4 Validation of the association between HUJRP mRNA and prognosis in three independent cohorts. Kaplan-Meier survival curves
for breast cancer patients according to tumor expression of HJURP are shown. The patients from each cohort were divided into a group with
high (top one-third), moderate (middle one-third) and low (bottom one-third) level of HJURP expression. HJURP expression is measured log2
(probe intensities) as in the microarray. The significant association between HJURP mRNA and disease-free and overall survival was validated in
three independent cohorts of patients with breast cancer. Parts (a), (b) and (c) show the Kaplan-Meier survival curves for disease-free and overall
survival in Dataset 1 (GSE1456), Dataset 2 (GSE7390) and Dataset 3 (NKI) respectively. The P-values shown were obtained from a long-rank test.
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Dataset 4 (Figure 5a) where almost all patients received
radiotherapy with or without additional benefit. Thus a
high level of HJURP is overall associated with poor
prognosis. Although we note our findings will require
replication in additional independent and larger cohorts,
our in vitro studies further confirmed that breast cancer
cells with high levels of HJURP are more sensitive to
radiation treatment, and even more convincingly, knock
down of HJURP by shRNA reduces the sensitivity to
radiation. The radiation induced more apoptosis in
these cells, consistent with clinical findings. A previous
report showed that HJURP interacts with proteins
hMSH5 and NBS1, suggesting HJURP is involved in the
DNA double-strand break repair process [7]. The under-
standing of the roles that HJURP plays in DNA repair
and cell death in response to DNA damage may provide
new insights into the molecular mechanisms of breast
tumor development and may help to improve breast
cancer therapies. In addition, we found that cells with
HJURP shRNA grew slowly (data not shown), which is
consistent with the finding that the double time of cell
lines was negatively correlated with HJURP protein level,
indicating HJURP plays an important role in cell prolif-
eration. Thus one of the reasons why the ability of
HJURP to act as a marker for prognosis and response to
radiotherapy may be linked to its control of cell
proliferation.
HJURP has recently been reported to interact with
CENP-A for the purpose of localizing CENP-A and
loading new CENP-A nucleosomes on the centromere
[11,12]. CENP-A is the key determinant of centromere
formation and kinetochore assembly, which regulate
the complex job of attaching chromosomes to the
mitotic spindle; ensuring that those attachments are
correct; signalling a delay in mitotic progression if they
are not, and regulating the movements of the chromo-
somes towards the spindle poles in anaphase. Thus
overexpression of HJURP in human breast cancer may
Table 5 Both HJURP mRNA levels and molecular subtypes are independent prognostic factors in patients with breast
cancer using Cox regression#
Disease-Free survival Overall survival
Factor Hazard ratio (95% CI) P value Hazard ratio (95% CI) P value
HJURP 6.19E-07 0.00011
High vs Low 3.26 (2.01 to 5.28) 1.72E-06 3.23 (1.85 to 5.62) 3.65E-05
Moderate vs Low 3.34 (2.11 to 5.27) 2.3E-07 2.89 (1.68 to 4.95) 0.00012
Molecular Subtypes 0.0069 0.00012
#The results are obtained from the combination of three data sets (reference 14, Dataset 1 and 3) where the information of the molecular subtypes (Normal like,
Luminal, Erbb2 and Basal) was available.
Figure 5 Validation of the association between HJURP mRNA and disease-free survival in another two independent cohorts. Kaplan-
Meier survival curves for breast cancer patients according to tumor expression of HJURP are shown. The patients from each cohort were divided
into a group with high (top one-third), moderate (middle one-third) and low (bottom one-third) level of HJURP expression. HJURP expression is
measured log2 (probe intensities) as in the microarray. The significant association between HJURP mRNA and disease-free survival was further
validated in two independent cohorts of patients with breast cancer. Parts (a) and (b) show the Kaplan-Meier survival curves for disease-free
survival in Dataset 4 (GSE2034) and Dataset 5 (GSE4922). The P-values shown were obtained from a long-rank test.
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Figure 6 The expression level of HJURP is a predictive factor for radiotherapy sensitivity. Kaplan-Meier survival curves for breast cancer
patients according to radiotherapy treatment are presented. Part (a) shows the survival curves for disease-free survival, while (b) shows survival
curves for overall survival. The P-values shown were obtained from a long-rank test.
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Figure 7 The HJURP mRNA level in breast cancer cell lines predicts the sensitivity to radiation treatment. Part (a) shows the percent of
viable cells at 72 hours after different doses of radiation in breast cancer cell line MDAMB231 with a high level of HJURP and T47D with a low
level of HJURP. MDAMD231 cells are more sensitive to radiation treatment than T47D cells. Figure 7b shows the fold change of apoptosis in
comparison to control (no radiation) at 72 hours after the different dose of radiation in breast cancer cell line MDAMB231 and T47D. There are
more apoptosis in MDAMB231 cells than T47D cells. Part (c) shows the percent of viable cells at 72 hours after the different dose of radiation in
breast cancer cell line BT20 with high level of HJURP and MCF10A with low level of HJURP. BT20 cells are more sensitive to radiation treatment
than MCF10A cells. Part (d) shows the fold change of apoptosis in comparison to control (no radiation) at 72 hours after the different dose of
radiation in breast cancer cell line BT20 and MCF10A. There are more apoptosis in BT20 cells than MCF10A cells. (e) HJURP protein levels are
down-regulated by shRNA in MDAMB231 breast cancer cell lines. Part (f) shows that MDAMB231 breast cancer cells with shRNA against HJURP
reduce the sensitivity to radiation.
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be similar to overexpression of mitotic kinases, such as
Aurora kinases, which induce genomic instability that
is one of the hallmarks for tumor development. In this
study we showed that HJURP mRNA levels are highly
significantly correlated with CENPA mRNA levels in
human breast cancer cell lines and primary breast
tumors. Such correlation is also found in other types
of human cancer, such as cancers from lung, ovary,
prostate (data not shown), suggesting that compatible
mRNA levels of HJURP and CENPA might be required
for tumor progression. Further investigation of the
interaction between HJURP and CENPA for breast
cancer development will be carried out in our future
studies.
Figure 8 Correlation between HJURP and CENPA in mRNA levels. There is a highly significant and positive correlation between HJURP and
CENPA in mRNA levels within human breast cancer cell lines (a), Primary breast tumors (b), Dataset 1 (c), Dataset2 (d), Dataset4 (e), and
Dataset5 (f). R shown is Spearman’s rho correlation coefficient.
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Conclusions
The expression level of HJURP has an independent
prognostic impact for both disease-free and overall sur-
vival in breast cancer, and is a predictive biomarker for
radiotherapy. Further investigations of the mechanisms
of HJURP in tumor development and its association
with sensitivity to radiotherapy are clearly warranted.
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